Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jin Medical International (ZJYL) Cash & Current Investments (2022 - 2025)

Jin Medical International's Cash & Current Investments history spans 4 years, with the latest figure at $29.6 million for Q3 2025.

  • For Q3 2025, Cash & Current Investments rose 10.74% year-over-year to $29.6 million; the TTM value through Sep 2025 reached $29.6 million, up 10.74%, while the annual FY2025 figure was $29.6 million, 10.74% up from the prior year.
  • Cash & Current Investments for Q3 2025 was $29.6 million at Jin Medical International, up from $26.8 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $29.6 million in Q3 2025 and bottomed at $4.8 million in Q3 2022.
  • The 4-year median for Cash & Current Investments is $21.7 million (2023), against an average of $19.5 million.
  • The largest annual shift saw Cash & Current Investments soared 248.42% in 2023 before it grew 10.74% in 2025.
  • A 4-year view of Cash & Current Investments shows it stood at $4.8 million in 2022, then skyrocketed by 248.42% to $16.7 million in 2023, then surged by 60.24% to $26.8 million in 2024, then rose by 10.74% to $29.6 million in 2025.
  • Per Business Quant, the three most recent readings for ZJYL's Cash & Current Investments are $29.6 million (Q3 2025), $26.8 million (Q3 2024), and $16.7 million (Q3 2023).